| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/06/2003 | WO2003010146A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof |
| 02/06/2003 | WO2003010135A1 Novel phenylpropionic acid derivatives |
| 02/06/2003 | WO2003010132A1 N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives |
| 02/06/2003 | WO2003010131A1 Alpha-ketoglutarates of active ingredients and compositions containing same |
| 02/06/2003 | WO2003009867A1 Use of biologically active hiv-1 tat, fragments or derivates thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 02/06/2003 | WO2003009860A1 Preparation used for the topical treatment of pains and skin diseases |
| 02/06/2003 | WO2003009855A2 Organo-phosphorous compounds for activating gamma/delta t cells |
| 02/06/2003 | WO2003009849A1 Process for the preparation of 2-(2-(4-(bis(4-fluorophenyl)methyl)-piperazin-1-yl)ethoxy)acetic acid derivatives or corresponding salt forms thereof and intermediates therefor |
| 02/06/2003 | WO2003009848A1 Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses |
| 02/06/2003 | WO2003009847A1 Substituted piperidines as modulators of the melanocortin receptor |
| 02/06/2003 | WO2003009845A1 Substituted urea neuropeptide y y5 receptor antagonists |
| 02/06/2003 | WO2003009843A1 Use of thiazole derivatives for preparing a medicine for protecting mitochondria |
| 02/06/2003 | WO2003009841A1 Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine |
| 02/06/2003 | WO2003009835A2 Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts |
| 02/06/2003 | WO2003009815A2 Compositions and methods for modulating blood-brain barrier transport |
| 02/06/2003 | WO2003009807A2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 02/06/2003 | WO2003009803A2 Method of improving cognitive function |
| 02/06/2003 | WO2003009800A1 Sustained-release therapeutic bioadhesive systems |
| 02/06/2003 | WO2003009741A2 Methods for treating joint inflammation, pain, and loss of mobility |
| 02/06/2003 | WO2002096433A9 Methods for treating delirium using glucocorticoid receptor-specific antagonists |
| 02/06/2003 | WO2002096423A3 Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways |
| 02/06/2003 | WO2002096420A3 Method for treating nerve injury caused by surgery |
| 02/06/2003 | WO2002093177A3 Assays for identifying modulators of rhomboid polypeptides |
| 02/06/2003 | WO2002079146A3 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 02/06/2003 | WO2002067851A3 Method for treating fibrotic diseases or other indications iiic |
| 02/06/2003 | WO2002064586A3 Heterocyclic inhibitors of erk2 and uses thereof |
| 02/06/2003 | WO2002063005A3 Lipid-associated molecules |
| 02/06/2003 | WO2002060424A3 Methods of using and compositions comprising sibutramine metabolites optionally in combination with other pharmacologically active compounds |
| 02/06/2003 | WO2002059112A3 Pyrazole compounds useful as protein kinase inhibitors |
| 02/06/2003 | WO2002058686A3 Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes |
| 02/06/2003 | WO2002053555A3 Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists |
| 02/06/2003 | WO2002048134A3 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists |
| 02/06/2003 | WO2002030937A3 Labeled resiniferatoxin derivatives for use in vanilloid receptor binding assay |
| 02/06/2003 | WO2002028904A3 Human anti-cd40 antibodies |
| 02/06/2003 | WO2002020722A3 Methods and compositions for in vitro targeting |
| 02/06/2003 | WO2002017895A3 Use of an aldosterone receptor antagonist to improve cognitive function |
| 02/06/2003 | WO2002013870A3 Formulation for administering therapeutic lipophilic molecules |
| 02/06/2003 | WO2002010137A9 Indazole derivatives as jnk inhibitors |
| 02/06/2003 | WO2001091801A3 Methods of transducing neural cells using lentivirus vectors |
| 02/06/2003 | WO2001077330A3 G protein-coupled receptors |
| 02/06/2003 | WO2001047946A3 GFRα1-RET SPECIFIC AGONISTS AND METHODS THEREFOR |
| 02/06/2003 | US20030028021 Chemical compounds |
| 02/06/2003 | US20030028008 Nucleotide sequences coding polypeptide for use in the treatment of urogenital, tumor, antherosclerotic and kidney disorders |
| 02/06/2003 | US20030028004 68730 and 69112, protein kinase molecules and uses therefor |
| 02/06/2003 | US20030027999 143 human secreted proteins |
| 02/06/2003 | US20030027983 Transport protein for use in the treatment of blood, hypertensive and epileptic disorders |
| 02/06/2003 | US20030027868 Aminoacetalization of camphor by reacting with NH4OH and suspending product in NaCl; preparation having a basic pH is then neutralised with nitric acid; product is an analogue of human cytokines |
| 02/06/2003 | US20030027867 Use of R-NSAID compounds for anti-HIV treatment |
| 02/06/2003 | US20030027852 Substituted pyrrolidine-2,3,4-trione 3-oxime deerivatives which are active as NMDA receptor antagonists |
| 02/06/2003 | US20030027851 Readily soluble crystal modification; specific X-ray diffraction pattern obtained with a focusing Debye-Scherrer beam and Cu-K alpha 1-radiation |
| 02/06/2003 | US20030027845 Ether derivatives useful as inhibitors of PDE4 isozymes |
| 02/06/2003 | US20030027841 Percutaneously applicable preparation and suppository containing an antidementia medicament |
| 02/06/2003 | US20030027840 Estrogen receptor modulators |
| 02/06/2003 | US20030027835 Trimebutine, N-desmethyltrimebutine, their metabolites or their stereoisomers and an opioid analgesic for treating pain or nociception. |
| 02/06/2003 | US20030027834 Modulating a pharmacological response from the ORL1 receptor for treating chronic pain |
| 02/06/2003 | US20030027832 4-Phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives |
| 02/06/2003 | US20030027831 Arylpiperzine derivatives are useful for treatment of anxiety, depression, hypertension, cognitive disorders, sexual dysfunction, brain trauma, memory loss, eating disorders, obesity, substance abuse, and obsessive-compulsive diseases |
| 02/06/2003 | US20030027822 Sodium channel modulators |
| 02/06/2003 | US20030027821 Administering 2-oxy substituted benzoxazin-5-one derivative to a human or animal for the prevention or treatment of obesity or an obesity related disorder |
| 02/06/2003 | US20030027820 Method for treating fibrotic diseases or other indications V |
| 02/06/2003 | US20030027812 Useful for treating or preventing a disorder or condition selected from hypertension, depression, anxiety, phobias, post trauma stress, sexual disfunction, eating disorder, obesity, Alzheimer's disease, Parkinson's disease etc. |
| 02/06/2003 | US20030027810 Nicotine receptor ligands |
| 02/06/2003 | US20030027807 Vitronectin receptor antagonists, their preparation and their use |
| 02/06/2003 | US20030027804 Administering to the mammal a menopause disorder effective amount of an orally deliverable pharmaceutically- acceptable sex hormone binding globulin synthesis inhibiting agent, and at least one of a non-orally deliverable steroids |
| 02/06/2003 | US20030027794 N-heterocyclic derivatives as NOS inhibitors |
| 02/06/2003 | US20030027755 Compositions and methods for the rescue of white matter |
| 02/06/2003 | US20030027752 Leucine-based motif and clostridial neurotoxins |
| 02/06/2003 | US20030027749 For use in therapy, and diagnostic assays |
| 02/06/2003 | US20030027743 Tripeptidylpeptidase inhibitors |
| 02/06/2003 | US20030027316 16051a and 16051b, novel human PDZ family members and uses thereof |
| 02/06/2003 | US20030027261 Novel genes TZap7/A, TZap7/B and TZap7 involved in T cell activation and uses thereof |
| 02/06/2003 | US20030027253 Nucleotides equences codin polypeptide for use in the treatment of cancer |
| 02/06/2003 | US20030027232 Novel compounds |
| 02/06/2003 | US20030027164 Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain |
| 02/06/2003 | US20030027158 Novel nucleic acid sequences encoding human breast tumor-associated protein 47-like polypeptides |
| 02/06/2003 | US20030026862 (+)-Cycloolivil as antioxidant obtained from a new natural source namely stereospermum personatum |
| 02/06/2003 | US20030026829 Analgesic patch |
| 02/06/2003 | US20030026803 Compositions for inhibiting macrophage activity |
| 02/06/2003 | US20030026796 Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase |
| 02/06/2003 | CA2857312A1 Nucleic acids, polypeptides, and methods for modulating apoptosis using deoxyhypusine synthase (dhs) |
| 02/06/2003 | CA2455602A1 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics |
| 02/06/2003 | CA2455580A1 Multipotent stem cells from peripheral tissues and uses thereof |
| 02/06/2003 | CA2454822A1 Nucleic acids, polypeptides, and methods for modulating apoptosis using apoptosis-specific eif-5a |
| 02/06/2003 | CA2454803A1 Probiotic bifidobacterium strains |
| 02/06/2003 | CA2454564A1 Process for the preparation of 2-(2-(4-(bis(4-fluorophenyl)methyl)-piperazin-1-yl)ethoxy)acetic acid derivatives or corresponding salt forms thereof and intermediates therefor |
| 02/06/2003 | CA2454562A1 Method of improving cognitive function |
| 02/06/2003 | CA2453919A1 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands |
| 02/06/2003 | CA2452328A1 Substituted piperidines as modulators of the melanocortin receptor |
| 02/06/2003 | CA2452259A1 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors |
| 02/06/2003 | CA2452159A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 02/06/2003 | CA2450073A1 Compositions and methods for modulating blood-brain barrier transport |
| 02/06/2003 | CA2448722A1 Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses |
| 02/05/2003 | WO2002014280A1 Piperidine derivatives and drugs containing these derivatives as the active ingredient |
| 02/05/2003 | EP1281775A2 Identification and use of molecules implicated in pain |
| 02/05/2003 | EP1281756A1 Regulator of calcineurin |
| 02/05/2003 | EP1281709A1 Novel heterocyclic compounds with anti-inflammatory activity |
| 02/05/2003 | EP1281707A1 Process for the preparation of 5-subtituted isobenzofurans |
| 02/05/2003 | EP1281324A2 Health food products |
| 02/05/2003 | EP1280918A2 Lipid metabolism enzymes |
| 02/05/2003 | EP1280909A2 Human lipocalin homologs and polynucleotides encoding the same |